Abstract

Background: Sleeping disorder is a debilitating condition of non-motor symptoms in patients with Parkinson’s disease (PD). Pramipexole could improve sleep disorders in PD patients, while repetitive transcranial magnetic stimulation (rTMS) also improves sleep in PD. However, there is no report on whether a combination therapy of Pramipexole with rTMS would produce a better therapeutic effect over administration of Pramipexole alone.

Objective: To evaluate the clinical effect of pramipexole combined with rTMS on sleep disorders in PD patients.

Methods: PD patients with sleep disorders were selected and divided into the control group and the treatment group using a random number table method. The control group was treated with pramipexole (0.25 mg tid), and the treatment group was treated with both pramipexole (0.25 mg tid) and rTMS. Baseline medications were continued in both groups. Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness Scale (ESS) were used quantitatively for sleep evaluation before and after treatment. The treatment course was 4 weeks.

Results: Sixty PD patients with sleep disorders were enrolled and divided into control (N = 30, age 68.0 ± 5.7-year-old) and treatment (N = 30, 67.6 ± 6.9-year-old) groups. The sleep scores were significantly decreased in both groups after treatment with Pramipexole (P < 0.01 and P < 0.01 in ESS and PQSI scores respectively) alone or combined with rTMS (P = 0.004 and P < 0.01). The effect size for ESS score was large (Cohen’s d = 0.91 and Cohen’s d = 1.01 respectively) and was even larger for PQSI score (Cohen’s d = 1.89 and Cohen’s d = 2.23 respectively) in the control and treatment groups. Additionally, combination of Pramipexole with rTMS had a better therapeutic effect (P = 0.028 and P = 0.001). The effect size for ESS score was medium (Cohen’s d = 0.58), while the effect size for PQSI score was larger (Table 1).

Conclusions: Combination therapy of Pramipexole with rTMS can further improve sleep quality in PD patients.

Keywords

Parkinson’s disease, Pramipexole, rTMS

Introduction

Parkinson’s disease (PD) is a progressive neurodegenerative disease. The clinical manifestations are characterized by resting tremor, bradykinesia, rigidity...
and postural instability. There are also non-motor symptoms (NMS) of PD such as early olfactory loss; sleep disorders such as insomnia; daytime sleepiness with sleep attacks; restless legs syndrome (RLS); and REM sleep behavior disorder (RBD). The main pathological changes are degeneration and loss of dopaminergic neurons in the substantia nigra causing dopamine depletion in the striatum, and the presence of Lewy bodies in the surviving neurons. The NMS in PD are related to widespread distribution of α-synuclein pathology which, in addition to the dopaminergic striatonigral system, involves non-nigral brainstem nuclei, sympathetic, parasympathetic, enteric and pelvic plexuses, cardiac systems, and other organs [1].

Levodopa is the main drugs for the treatment of PD. Its effectiveness may fade over the course of treatment and then cause significant motor fluctuations, such as on-off, wearing off, freezing, involuntary movements in patients [2]. Pramipexole, a non-ergot dopamine receptor agonist, can be used as monotherapy or adjunct agent to treat many PD symptoms such as stiffness, tremors, muscle spasms, and poor muscle control alone or together with levodopa in treating advanced PD patients. Early use of pramipexole may delay or prevent levodopa-induced dyskinesia and motor fluctuations, and may postpone the need for levodopa treatment for several years [3].

PD medications may interfere with sleep circadian causing insomnia at night and hypersomnia during daytime which significantly impact quality of daily living [4]. Sleep disorders including insomnia, daytime sleepiness with sleep attacks, RLS, and RBD affect between 55 and 80 percent of PD patients [5, 6]. Significantly, sleep disorders aggravate patients’ cognitive impairment and mental symptoms. Notably, sleep difficulty was ranked as one of the most troublesome nonmotor symptoms in a survey of PD patients of both early- and late-stage [7].

Repetitive transcranial magnetic stimulation (rTMS) is a new neuroelectrophysiological technology that excites or inhibits local cerebral cortical function by changing the stimulation frequency. rTMS can be dosed with high and low frequencies. High frequency (HF) is frequency above 1 Hz, more typically set at ~10 Hz. HF has been shown to have an excitatory effect [8]. On the other hand, low frequency (LF) rTMS includes frequencies 1 Hz and below. LF rTMS, when used continuously, is thought to be inhibitory [8]. Pascual-Leone et al. first applied TMS to the treatment of PD patients in 1994 and achieved significantly beneficial results [9]. Positive effect of TMS on sleep in PD patients was also reported [10]. A recently randomized, sham-controlled study demonstrated that LF rTMS over the right dorsolateral prefrontal cortex (DLPFC) improved motor symptoms, depression and cognitive performance in patients with PD [11]. LF rTMS on right DLPFC could be a potential selection in managing motor and nonmotor symptoms in PD [11]. There are a growing number of TMS studies on treating PD symptoms and sleep disorders in those patients. Van Dijk et al. studied sleep using actigraphy and a pressure sensitive pad in 13 patients with PD using 5 Hz rTMS over the motor or the parietal cortex. rTMS over the parietal, but not the motor cortex improved sleep fragmentation and sleep efficiency and decreased the average duration of nocturnal awakenings [10].


d Antczak and colleagues studied 11 patients (10 completed) using 15 Hz rTMS bilaterally over the primary motor areas at 120% Motor Threshold (MT), using the PD Sleep Scale and PSG findings, they found decreased NREM stage 1 and nocturnal arousals as well as subjective improvement by patient’s report. Jiang and colleagues reported rTMS improved both slow wave sleep and REM sleep [12]. LF rTMS stimulating the right DLPFC or the posterior parietal cortex was found to be effective to reduce cortical hyperexcitability and improve the sleep quality in subjects with chronic primary insomnia [13]. rTMS treatment can improve the sleep architecture and significantly decreases the body awakening level and provides a better long-term treatment effect [11]. The modulatory effect was locally inhibited when 1Hz rTMS was applied to the occipital cortex [14]. However, controversy exists. A study of LF rTMS over the vertex on sleep in PD did not show significant clinical benefit [15].

Although administration of either pramipexole or rTMS improves the sleeping circadian in PD patients, there are currently no reports on combination of pramipexole with rTMS in the treatment for PD sleep disorders. This study aims to observe whether combination of pramipexole with rTMS bears a better therapeutic effect over pramipexole or rTMS alone on sleep disorders in PD patients.

**Materials and Methods**

**Patient selection**

Inclusion criteria: 1. Meet the PD diagnostic criteria [16]; 2. Able to complete the test scale evaluation; 3. Age ≤ 80 years

**Table 1: General information, ESS and PQSI scores and statistical analysis of the control and treatment groups.**

| Group                | Gender (Male, %) | Age (year-old) | Courses (year) | ESS score | PQSI score |
|----------------------|------------------|----------------|----------------|-----------|------------|
|                      |                  |                |                | Before    | After      |
|                      |                  |                |                | P value   | Cohen’s d  |
| Control (n = 30)     | 20 (66.7)        | 68.0 ± 5.7     | 4.6 ± 2.9      | 7.20 ± 1.51 | 6.01 ± 1.08 | 0.004  | 0.91 | 8.22 ± 1.84 | 5.27 ± 1.23 | < 0.001 | 1.89 |
| Treatment (n = 30)   | 15 (50)          | 67.6 ± 6.9     | 3.0 ± 1.9      | 6.45 ± 1.05 | 5.48 ± 0.71 | < 0.001 | 1.01 | 7.82 ± 2.04 | 3.49 ± 1.41 | < 0.001 | 2.23 |
| P value              | 0.719            | 0.823          | 0.194          | 0.095     | 0.028      |         | 0.428 | 0.0011      |
| Cohen’s d            |                  |                |                |          |            |         |      |             |
old; 4. Willing to participate in this research study and sign
an informed consent form. Exclusion criteria: 1. Parkinsonism
(including traumatic, tumor, drug-induced, toxic, vascular
and hydrocephalus, etc.) and Parkinson-plus syndromes; 2.
Having other diseases that may affect sleep such as chronic
obstructive pulmonary disease, coronary heart disease, and
stroke; 3. Patients with a history of brain surgery or epilepsy;
4. Pacemakers or intracranial stents and other metal implants;
5. Severe diseases of other systems; 6. Those who cannot
cooperate with treatment.

Sixty PD patients with sleep disorders were selected
based on the inclusion criteria from the pool of PD patients
who were seen at the clinic of the Department of Neurology in
the Affiliated Hospital of Weifang Medical College between
October 2019 and March 2020. These patients were randomly
divided into two groups by a random number table, 30 patients
in each group.

Setting

Control group

All patients continued to have the original dose of
Levodopa and Benserazide hydrochloride tablets for basic
treatment, plus pramipexole hydrochloride tablets (Boehringer
Ingelheim Pharmaceutical Co., Ltd.). The initial dose was
0.25 mg/day, and then the dose was increased every 7 days.
If the patient could tolerate it, the dose should be increased
to achieve the maximum effect. The treatment plan for each
patient was personalized, starting with a low dose, gradually
titrating up the dose and the treatment course was 4 weeks.

Treatment group

TMS treatment was added to the treatment regimen
for the control group. The TMS treatment parameters were
the same. The frequency was 1 Hz, and 80% of the motor
threshold (MT) stimulation intensity was given. The target
was in the right DLPFC and occipital area. Each target point
was given 600 pulses in 20 minutes per day. The treatment
course was 10 days.

Main outcome measures

The patients were evaluated before and after treatment
using the Pittsburgh Sleep Quality Index (PSQI) and
Epworth Sleepiness Scale (ESS). The scores of the patients’
sleep status was recorded.

Statistical analysis

SPSS 21.0 statistical software was used to analyze the
data. All the data was expressed as mean ± standard deviation.
Paired t-test was used for pairwise comparisons within groups.
Independent-sample t-test was used for pairwise comparisons
between groups; χ² test was used for comparisons between
groups. P < 0.05 indicated that the difference was significant.

Cohen’s d was used to measure the effect size. Effect size
is a quantitative measure of the magnitude of the treatment
effect. The larger the effect size the stronger the relationship
between the control and treatment groups. Small effect = 0.2;
Medium Effect = 0.5; Large Effect = 0.8.

Results

There were 20 males and 10 females in the control group
with an average age of 68.0 ± 5.7-year-old, 15 males and 15
females in the treatment group with an average age of 67.6 ±
6.9-year-old. The age range of selected patients was between
51 and 80-year-old. There was no significant difference
between the two groups such as gender, age, course of disease,
etc., (p > 0.05) (Table 1).

The ESS scores were obtained before and after the
treatment, it was 7.20 ± 1.51 and 6.01 ± 1.08 for the control
group, and 6.45 ± 1.05 and 5.48 ± 0.71 for the treatment group.
There was no significant difference between the two groups
before (P = 0.095), but significant difference after treatment (P
= 0.028). There were significant differences before and after
treatment within each group (P < 0.05). The effect size for
ESS score before and after treatment was large in the control
group (Cohen’s d = 0.91) and in the treatment group (Cohen’s
d = 1.01) (Table 1).

The PSQI scores were obtained before and after the
management in both groups. The scores were 8.22 ± 1.84
and 5.27 ± 1.23 for the control group; 7.82 ± 2.04 and 3.49 ± 1.41
for the treatment group. There was no significant difference
between these two groups before treatment (P = 0.428), but
significant difference after treatment (P = 0.001) (Table 1).
The effect size was large for PSQI score before and after
treatment in the control group (Cohen’s d = 1.89) and in the
treatment group (Cohen’s d = 2.23) (Table 1).

There were significant differences before and after treatment
within each group (P < 0.001). Additionally, combination
of Pramipexole with rTMS had a better therapeutic effect
(P = 0.028 and P = 0.001). The effect size for ESS score was
medium (Cohen’s d = 0.58), while the effect size for PSQI
score was larger (Cohen’s d = 1.35) (Table 1).

Discussion

Motor symptoms are the main clinical manifestations of
PD. NMS gradually increase its impact on the quality of life in
PD patients as the disease progresses. The presence of a REM
sleep behavior disorder in PD patients might reflect the early
involvement of dopaminergic neurotransmission in REM
sleep-related structures [17] and these structures are affected
by imbalanced dopamine levels. Neurons in the substantia
nigra pars compacta and in the ventral tegmental area are
active during REM sleep and sleep-related disorders may
occur when these neurons are targeted such as by neurotoxins
[17].

Levodopa continues to be a cornerstone agent in treating
PD motor symptoms, however, it may also aggravate the
patient’s NMS. Side effects of levodopa therapy vary which
may cause debilitating iatrogenic conditions including
psychiatric symptoms, dyskinesias, or motor fluctuations
such as the wearing-off or on-off phenomena. Clinically
available new medications such as dopamine receptor agonist
have several advantages over levodopa. Nowadays, dopamine
receptor agonists can be used as the first choice as monotherapy.
for young parkinsonian patients to postpone the initiation of levodopa therapy. For patients with PD at advanced stages, they can also be used as adjunct therapy together with levodopa to retard the development of levodopa-induced motor complications. Pramipexole is a one of the dopamine receptor agonists and is a synthetic derivative of thiazole. Pramipexole stimulates dopamine receptors in the striatum and restore the dopamine signals required for normal function of the basal ganglia in PD patients, thereby achieving the effect of treating PD [18, 19]. Pramipexole binds to the dopamine D1/D2 receptors in the emotional regulation area outside the striatum and improves dopamine effects on cerebral cortex-frontal lobe and limbic system [20]. Experimental in vitro and in vivo studies suggest neuroprotective activities of pramipexole via its dopamine auto receptor agonist property as well as interaction with the D3 receptor, including antioxidant effect, blocking mitochondrial permeability of transition pore, stimulating release of trophic factors, inhibiting apoptotic pathways, promoting expression of neurotrophic factors [20].

In our control group, the ESS and PSQI scores were significantly reduced after 4-week of treatment with pramipexole only (P < 0.01). The effect size was large for ESS score (Cohen's d = 0.91) and large for PSQI scores (Cohen's d = 1.89) (Table 1). Our study also showed that Pramipexole can improve the symptoms of sleep disorders in PD patients.

rTMS is a simple and safe neuro-electrophysiological technology that can effectively stimulate the cerebral cortex by magnetic signals that can pass through the skull without attenuation. When rTMS acts on the cortex in a specific area, it can induce the release of dopamine under the cortex, improve cortical excitability and normalize abnormally activated local neuronal networks, thereby improving clinical symptoms [21]. rTMS has been reported to be effective for PD and this technique is gradually being widely used clinically [22]. Factors affecting rTMS include stimulation of the anatomic target, intensity and frequency [14]. Among these factors, low range of frequency seems to be the most important parameter of rTMS [23]. Additionally, rTMS has broad effects on various neurotransmitters and their transmission in the brain, a variety of receptors including those for serotonin and N-formyl D-aspartate in different brain locations. It can also modulate the expression of genes that regulate neuronal excitability underlying mechanisms that regulate the state of brain function [21, 24, 25]. On the other hand, NMS may be related to a variety of neurotransmitter metabolism disorders such as 5-hydroxytryptamine (5HT), norepinephrine (NE), dopamine (DA) [26]. It has been hypothesized that 5-HT plays a role in sleep-wake cycle controlling and also promotes the release of ε-aminobutyric acid, which slows down neuronal activity, and inhibits the related functions of the reticular ascending activation system distributed on the brainstem, non-rapid eye movement sleep increases, thereby improving the patient's sleep quality [27–30]. Apparently, treating NMS can also improve the patients' quality of life.

In this study, the ESS score of the treatment group was significantly lower than those before treatment (P < 0.001), the effect size was large (Cohen's d = 1.01); the PSQI score of the treatment group also was significantly lower than those before treatment (P < 0.001), the effect size was large (Cohen's d = 2.23). The ESS and PSQI scores were significantly lower than those of the control groups (P = 0.028 and P = 0.0011 respectively), with medium and large effect size for ESS and PSQI scores respectively (Cohen's d = 0.58 and Cohen's d = 1.35) (Table 1), indicating that pramipexole combined with rTMS has a significant effect on sleep disorders in PD patients.

In conclusion, Pramipexole can improve the symptoms of sleep disorders in PD patients. Pramipexole combined with rTMS can provide a better therapeutic effect on sleep disorders in PD patients and further improve their quality of life.

Further randomized, sham-controlled studies with large number of patients are needed in the future as the current study did not include sham control with small sample numbers. Quantitate sleep scoring, cognitive scoring, depression scoring, and different sleep types of analysis could also be included in further studies.

Acknowledgment

The authors would like to thank Dr. James Wang and Dr. Dong Wang for help revising the manuscript and Dr. Henian Chen for help with statistics.

References

1. Jellinger KA. 2015. Neuropathobiology of non-motor symptoms in Parkinson disease. J Neural Transm (Vienna) 122(10): 1429-1440. https://doi.org/10.1007/s00702-015-1405-5
2. Bennett JP Jr, Piercey MF. 1999. Pramipexole- a new dopamine agonist for the treatment of Parkinson’s disease. J Neurol Sci 163(1): 25-31. https://doi.org/10.1016/s0022-510x(98)00307-4
3. Salawu FK. 2012. Patient considerations in early management of Parkinson’s disease: focus on extended-release pramipexole. Patient Prefer Adherence 6: 49-54. https://doi.org/10.2147/PAA.S11841
4. Videnovic A, Noble C, Reid KJ, Peng J, Turek FW, et al. 2014. Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease. JAMA Neurol 71(4): 463-469. https://doi.org/10.1001/jamaneurol.2013.6239
5. Tandberg E, Larsen JP, Karlsen K. 1998. A community-based study of sleep disorders in patients with Parkinson’s disease. Mov Disord 13 (6): 895–899. https://doi.org/10.1002/mds.870130606
6. Ozerlemens WGH, de Weerd AW. 2002. The prevalence of sleep disorders in patients with Parkinson’s disease. A self-reported, community-based survey. Sleep Med 3(2): 147-149. https://doi.org/10.1016/s1389-9457(01)00127-7
7. Politis M, Wu K, Molloy S, Bain PG, Chaudhuri KR, et al. 2010. Parkinson’s disease symptoms: the patient’s perspective. Mov Disord 25(11): 1646–1651. https://doi.org/10.1002/mds.23135
8. Valero-Cabre A, Amengual JL, Stengel C, Pascual-Leone A, Couhard O.A. 2017. Transcranial magnetic stimulation in basic and clinical neurosciences: a comprehensive review of fundamental principles and novel insights. Neurosci Biobehav Rev 83: 381–404. https://doi.org/10.1016/j.neubiorev.2017.10.006
9. Pascual-Leone A, Valls-Sole J, Wassermann EM, Hallet M. 1994. Responses to rapid-rate transcranial magnetic stimulation of the human motor cortex. Brain 117(Pr 4): 847-858. https://doi.org/10.1093/brain/117.4.847
The Effect of Pramipexole Combined with rTMS on Sleep Disorders in Parkinson’s Disease Patients

Wang et al.

10. van Dijk KD, Most EIS, Van Someren EJW, Berendse HW, van der Werf YD. 2009. Beneficial effect of transcranial magnetic stimulation on sleep in Parkinson’s disease. Mov Disord 24(6): 878-884. https://doi.org/10.1002/mds.22462

11. Zhuang S, Wang F-Y, Gu X, Wu J-J, Mao C-J, et al. 2020. Low-frequency repetitive transcranial magnetic stimulation over right dorso-lateral prefrontal cortex in Parkinson’s disease. Parkinsons Dis 2020. https://doi.org/10.1155/2020/7295414

12. Jiang C-G, Zhang T, Yue F-G, Yi M-L, Gao D. 2013. Efficacy of repetitive transcranial magnetic stimulation in the treatment of patients with chronic primary insomnia. Cell Biochem Biophys 67(1): 169-173. https://doi.org/10.1007/s12013-013-9529-4

13. Nardone R, Sebastianelli L, Versace V, Brigo F, Golaszewski S, et al. 2020. Effects of repetitive transcranial magnetic stimulation in subjects with sleep disorders. Sleep Med 71: 113-121. https://doi.org/10.1016/j.sleep.2020.03.028

14. Orez R, Kung S, Croarkin PE, Cheung J. 2021. Transcranial magnetic stimulation therapeutic applications on sleep and insomnia: a review. Sleep Sci Pract 5: 3. https://doi.org/10.1186/s41606-020-00057-9

15. Arias P, Vivas J, Grieve KL, Cudeiro J. 2010. Double-blind, randomized, placebo controlled trial on the effect of 10 days low-frequency rTMS over the vertex on sleep in Parkinson’s disease. Sleep Med 11(8): 759-765. https://doi.org/10.1016/j.sleep.2010.05.00

16. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, et al. 2015. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30(12): 1591-1601. https://doi.org/10.1002/mds.26424

17. Lima MMS. 2013. Sleep disturbances in Parkinson’s disease: the contribution of dopamine in REM sleep regulation. Sleep Med Rev 17(5): 367-375. https://doi.org/10.1016/j.smrv.2012.10.006

18. Poewe W, Rascol O, Barone P, Hauser RA, Mizuno Y, et al. 2011. Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial. Neurology 77(8): 759-766. https://doi.org/10.1212/WNL.0b013e318222af80

19. Olanow CW, Kieburz K, Leinonen M, Elmer L, Giladi N, et al. 2017. A randomized trial of a low-dose Rasagiline and Pramipexole combination (P+B) in early Parkinson’s disease. Mov Disord 32(5): 783-789. https://doi.org/10.1002/mds.26941

20. Radak K, Gille G, Rausch W-D. 2005. Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson’s disease. Pharmacol Rep 57(6): 701-712

21. Yang Y-R, Tseng C-Y, Chiu S-Y, Liao K-K, Cheng S-J, et al. 2013. Combination of rTMS and treadmill training modulates corticomotor inhibition and improves walking in Parkinson disease: a randomized trial. Neurorhabil Neural Repair 27(1): 79-86. https://doi.org/10.1177/154968312451915

22. Zhu HC, Lu ZM, Jin YT, Duan XJ, Teng JF, et al. 2015. Low-frequency repetitive transcranial magnetic stimulation on Parkinson motor function: a meta-analysis of randomised controlled trials. Acta Neuropsychiatr 27(2): 82-89. https://doi.org/10.1017/neu.2014.43

23. Haslinger B, Erhardt P, Kampsfe N, Boecker H, Rummeny E, et al. 2001. Event-related functional magnetic resonance imaging in Parkinson’s disease before and after levodopa. Brain 124(Pt 3): 558-570. https://doi.org/10.1093/brain/124.3.558

24. Nardone R, De Biasi P, Holler Y, Christova M, Tezzon F, et al. 2014. Repetitive transcranial magnetic stimulation transiently reduces periodic limb movement in Parkinson’s disease: a preliminary study. J Neural Transm (Vienna) 121(3): 267-274. https://doi.org/10.1007/s00702-013-1100-3

25. Shah BB, Chen R, Zuworski M, Kalia LV, Gunraj C, et al. 2015. Repetitive transcranial magnetic stimulation plus standardized suggestion of benefit for functional movement disorders: an open label case series. Parkinsonism Relat Disord 21(4): 407-412. https://doi.org/10.1016/j.parkreldis.2015.01.013

26. Yuan Y-S, Zhou X-J, Tong Q, Zhang L, Zhang L, et al. 2013. Change in plasma levels of amino acid neurotransmitters and its correlation with clinical heterogeneity in early Parkinson’s disease patients. CNS Neurosci Ther 19(11): 889-896. https://doi.org/10.1111/cns.12165

27. Mallotra RK. 2018. Neurodegenerative disorders and sleep. Sleep Med Clin 13(1): 63-70. https://doi.org/10.1016/j.smcl.2017.09.006

28. Mischley IK. 2017. Nutrition and nonmotor symptoms of Parkinson’s disease. Int Rev Neurobiol 134: 1143-1161. https://doi.org/10.1016/bs.irn.2017.04.013

29. Du X, Xu W, Li X, Zhou D, Han C. 2019. Sleep disorder in drug addiction: treatment with transcranial magnetic stimulation. Front Psychiatry 10: 848. https://doi.org/10.3389/fpsyt.2019.00848

30. Sanches C, Levy R, Benisty S, Volpe-Gillett L, Habert MO, et al. 2019. Testing the therapeutic effects of transcranial direct current stimulation (tDCS) in semantic dementia: a double blind, sham controlled, randomized clinical trial. Trials 20(1): 632. https://doi.org/10.1186/s13063-019-3613-z